Kishimoto K, Dong V M, Issazadeh S, Fedoseyeva E V, Waaga A M, Yamada A, Sho M, Benichou G, Auchincloss H, Grusby M J, Khoury S J, Sayegh M H
Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Clin Invest. 2000 Jul;106(1):63-72. doi: 10.1172/JCI9586.
We used signal transducer and activator of transcription 4 (STAT4) and STAT6 gene knockout (-/-) mice as recipients of fully mismatched cardiac allografts to study the role of T-cell costimulatory pathways in regulating allogeneic T-helper 1 (Th1) versus Th2 responses in vivo. STAT4(-/-) mice have impaired Th1 responses, whereas STAT6(-/-) mice do not generate normal Th2 responses. Cardiac allografts from C57BL/6 mice were transplanted into normal wild-type (WT), STAT4(-/-), and STAT6(-/-) BALB/c recipients. STAT4(-/-) and STAT6(-/-) mice rejected their grafts with the same tempo as untreated WT recipients. CD28-B7 blockade by a single injection of CTLA4Ig induced long-term engraftment and donor-specific tolerance in all three groups of recipients. CD154 blockade by a single injection of MR1 was effective in prolonging allograft survival and inducing tolerance in STAT4(-/-) mice but was only marginally effective in STAT6(-/-) recipients and WT controls. In addition, a similar protocol of MR1 was ineffective in prolonging graft survival in CD28(-/-) BALB/c recipients, suggesting that the lack of efficacy seen in WT and STAT6(-/-) mice is not due to the presence of a functional CD28-B7 pathway. Furthermore, there was a similar differential effect of CD28-B7 versus CD154-CD40 blockade in inhibiting immune responses in animals immunized with ovalbumin and complete Freund's adjuvant. These novel data indicate that Th1 and Th2 cells are differentially regulated by CD28-B7 versus CD154-CD40 costimulation pathways in vivo and may have potential implications for the development of therapeutic strategies such as T-cell costimulatory blockade in humans.
我们使用信号转导子和转录激活子4(STAT4)及STAT6基因敲除(-/-)小鼠作为完全不匹配心脏同种异体移植物的受体,以研究T细胞共刺激途径在体内调节同种异体辅助性T细胞1(Th1)与Th2反应中的作用。STAT4(-/-)小鼠的Th1反应受损,而STAT6(-/-)小鼠不能产生正常的Th2反应。将C57BL/6小鼠的心脏同种异体移植物移植到正常野生型(WT)、STAT4(-/-)和STAT6(-/-)的BALB/c受体小鼠体内。STAT4(-/-)和STAT6(-/-)小鼠排斥其移植物的速度与未治疗的WT受体小鼠相同。单次注射CTLA4Ig阻断CD28 - B7可在所有三组受体小鼠中诱导长期植入和供体特异性耐受。单次注射MR1阻断CD154可有效延长STAT4(-/-)小鼠的同种异体移植物存活时间并诱导耐受,但在STAT6(-/-)受体小鼠和WT对照中仅具有微弱效果。此外,类似的MR1方案在延长CD28(-/-)BALB/c受体小鼠的移植物存活时间方面无效,这表明在WT和STAT6(-/-)小鼠中观察到的无效并非由于功能性CD28 - B7途径的存在。此外,在使用卵清蛋白和完全弗氏佐剂免疫的动物中,CD28 - B7与CD154 - CD40阻断在抑制免疫反应方面存在类似的差异效应。这些新数据表明,在体内Th1和Th2细胞受CD28 - B7与CD154 - CD40共刺激途径的调节存在差异,这可能对人类T细胞共刺激阻断等治疗策略的开发具有潜在意义。